PMC Buys Isochem’s Pharma Business

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

PMC Group France, a wholly owned subsidiary of US-based PMC Group International, has acquired the pharmaceuticals business of France’s Isochem for an undisclosed sum.

The business comprises research, product and process development capabilities as well as pilot-scale and full plant-scale production of drug intermediates and APIs for major companies worldwide.

Isochem operates three sites at Gennevilliers, Pithiviers and Vert-le-Petit, all within a 60-mile radius of Paris and audited by the US Food and Drug Administration (FDA) as cGMP-compliant.

Going forward, the company will be known as PMC Isochem, operating as a wholly owned subsidiary of PMC Group France.

The acquisition follows the October purchase of Indian pharma Yegna Manojavam Drugs and Chemicals by PMC Group subsidiary, PMC YM-Pharma. The Indian company’s cGMP plant is claimed to be one of the largest fluoroquinolone drug manufacturing facilities in France.

Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.